1	Single nucleotide variants in <i>Pseudomonas aeruginosa</i> populations from sputum correlate
2	with baseline lung function and predict disease progression in individuals with cystic fibrosis
3	
4	Morteza M. Saber ^{#1} , Jannik Donner ^{#2} , Inès Levade ² , Nicole Acosta ³ , Michael D. Parkins ^{3,4} , Brian
5	Boyle ⁵ , Roger Levesque ⁵ , Dao Nguyen ^{1,2,6*} and B. Jesse Shapiro ^{1,7*}
6	
7	¹ Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
8	² Department of Medicine, Research Institute of the McGill University Health Centre, Montreal,
9	Quebec H4A 3J1, Canada
10	³ Department of Microbiology, Immunology and Infectious Disease, University of Calgary,
11	Calgary, AB, Canada.
12	⁴ Department of Medicine, University of Calgary, Calgary, AB, Canada.
13	⁵ Integrative Systems Biology Institute, Université Laval, Québec, Canada
14	⁶ Meakins Christie Laboratories, Research Institute of the McGill University Health Centre,
15	Montreal, QC, Canada
16	⁷ McGill Genome Centre, Montreal, QC, Canada
17	
18	
19	* Corresponding authors
20	E-mail: dao.nguyen@mcgill.ca, jesse.shapiro@mcgill.ca
21	[#] These authors contributed equally to this work
22	

23 Abstract

24 Complex polymicrobial communities inhabit the lungs of individuals with cystic fibrosis (CF) and 25 contribute to the decline in lung function. However, the severity of lung disease and its progression 26 in CF patients are highly variable and imperfectly predicted by host clinical factors at baseline, 27 CFTR mutations in the host genome, or sputum polymicrobial community variation. The 28 opportunistic pathogen Pseudomonas aeruginosa (Pa) dominates airway infections in the majority 29 of CF adults. Here we hypothesized that genetic variation within Pa populations would be predictive of lung disease severity. To quantify Pa genetic variation within whole CF sputum 30 samples, we used deep amplicon sequencing on a newly developed custom Ion AmpliSeq panel of 31 32 209 Pa genes previously associated with the host pathoadaptation and pathogenesis of CF 33 infection. We trained machine learning models using Pa single nucleotide variants (SNVs), 34 clinical and microbiome diversity data to classify lung disease severity at the time of sputum sampling, and to predict future lung function decline over five years in a cohort of 54 adult CF 35 36 patients with chronic Pa infection. The models using Pa SNVs alone classified baseline lung 37 disease with good sensitivity and specificity, with an area under the receiver operating 38 characteristic curve (AUROC) of 0.87. While the models were less predictive of future lung 39 function decline, they still achieved an AUROC of 0.74. The addition of clinical data to the models, 40 but not microbiome community data, yielded modest improvements (baseline lung function: AUROC=0.92; lung function decline: AUROC=0.79), highlighting the predictive value of the 41 42 AmpliSeq data. Together, our work provides a proof-of-principle that Pa genetic variation in 43 sputum is strongly associated with baseline lung disease, moderately predicts future lung function 44 decline, and provides insight into the pathobiology of Pa's effect on CF.

45

46 Importance

47 Cystic fibrosis (CF) is among the most common, life-limiting inherited disorder, caused by 48 mutations in the CF transmembrane conductance regulator (CFTR) gene. CF causes progressive 49 damage to the lungs, the major cause of morbidity and mortality in CF patients. However, the rate 50 of lung function decline is highly variable across CF patients, and cannot be fully explained using 51 existing biomarkers in the human genome or patient co-morbidities. Pseudomonas aeruginosa 52 (Pa) is known to evolve and adapt within chronic CF infections. We hypothesized that withinpatient Pa diversity could affect lung disease severity. In a CF cohort study, we demonstrate the 53 54 utility of machine learning tools for predictive modeling of baseline lung function and subsequent decline in CF patients using deep within-patient Pa amplicon sequencing. Our findings show the 55

56 potential of these models to identify high-risk CF patients based on *Pa* diversity within the lung.

57 Introduction

58 Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF 59 transmembrane conductance regulator (CFTR) gene and is the most common lethal Mendelian 60 disease in populations with European ancestry (Welsh, Ramsey et al. 2001). The resulting lung 61 disease is the major cause of morbidity and mortality in CF patients, with lung failure the most 62 common cause of death (Turcios 2020). However, the rate of disease progression and lung function 63 decline is highly variable across CF populations, and cannot be fully explained by variations in 64 CFTR alleles or other modifier genes (Shanthikumar, Neeland et al. 2019).

65

66 While CF airway infections are polymicrobial and microbiome diversity has been associated with 67 lung disease severity in many studies such as (Cox, Allgaier et al. 2010, van der Gast, Flight, Smith 68 et al. 2015, Zhao, Schloss et al. 2012, Coburn, Wang et al. 2015, Cuthbertson, Walker et al. 2020), 69 Pseudomonas aeruginosa (Pa) is recovered in the majority of adult CF patients and often 70 dominates the CF airway microbiome once established as a chronic infection (Goddard, Staudinger 71 et al. 2012, Zhao, Schloss et al. 2012). Infection with Pa in early life is widely recognized to be 72 associated with a greater decline in lung function and mortality (Kosorok, Zeng et al. 2001, 73 Emerson, Rosenfeld et al. 2002, Fothergill, Walshaw et al. 2012). Notably, Pa airway infections 74 can persist even with highly effective CFTR-correcting treatment (Hisert, Heltshe et al. 2017, 75 Harris, Wagner et al. 2020).

76

77 Over the course of chronic infection in the CF lung, Pa undergoes genetic diversification, selection 78 and adaptive evolution, resulting in a genetically and phenotypically diverse population of 79 clonally-related Pa within each patient (Tümmler 2006, Smith, Buckley et al. 2006, Bragonzi, 80 Paroni et al. 2009, Mowat, Paterson et al. 2011, Folkesson, Jelsbak et al. 2012, Marvig, Sommer 81 et al. 2015). How this pathoadaptation affects the clinical course of CF lung disease remains poorly 82 understood. We therefore focused on examining the association between Pa genetic variation and 83 the severity and progression of lung disease in CF patients with chronic Pa infections. We 84 hypothesized that the within-host genetic variation in Pa populations during chronic CF lung 85 infections are associated with baseline lung function and subsequent progression (i.e. decline in 86 lung function), as measured by spirometry.

87 Within-host mutations can significantly affect the virulence of Pa and host responses to Pa, 88 (Marvig, Johansen et al. 2013, Marvig, Sommer et al. 2015, Williams, Evans et al. 2015, 89 Klockgether, Cramer et al. 2018, Dettman and Kassen 2021). Previous studies have examined the 90 genetic variation of Pa across cohorts of CF patients by performing whole-genome sequencing 91 (WGS) of one or few Pa clones isolated from CF sputum samples – an approach that fails to 92 capture the polyclonal nature of Pa in the CF lung and is subject to profound sampling bias. While 93 shotgun metagenomic analysis of CF sputum is increasingly used for microbiome analyses 94 (Nelson, Pope et al. 2019, Whelan, Waddell et al. 2020, Lim et al. 2014,), the overwhelming 95 abundance of host derived DNA in samples continues to hamper the ability to resolve within 96 species genetic variation. To overcome these challenges, here we applied a custom-made amplicon 97 sequencing (AmpliSeq) panel of 209 genes in the *Pa* genome previously known to be involved in 98 the pathoadaptation and pathogenesis of CF infections (Supplementary Data 1). The Ion AmpliSeq 99 platform was selected because it provides a means for quantitative and sensitive measurement of 100 single nucleotide variant (SNV) frequencies within the Pa population, directly from CF sputum 101 without the need to culture and sequence hundreds of isolates per individual sample.

102

103 We then used several machine learning (ML) approaches to classify lung disease severity (at the 104 time of sample collection) and to predict future disease progression (over five years) based on the 105 SNV frequency data from a cohort of 54 adult CF patients with chronic Pa infection. ML has been 106 successfully applied to predict phenotypes from genotype data in other model systems (Dias and 107 Torkamani 2019). ML models can explicitly include the interactions and correlations between 108 features (in our case, SNVs), which is particularly common in bacterial population structures in 109 which SNVs are often genetically linked on the same clonal genomic background (Lees, Mai et al. 110 2020).

111

112 Our study provides proof-of-principle evidence that the population of Pa in CF sputum includes 113 bacterial genetic biomarkers that are associated with lung disease status and could serve to identify 114 individuals at increased risk of future lung function decline. Additionally, this work identified 115 genetic variation in Pa genes that merit further investigation for their potential roles in the 116 pathogenesis of CF lung disease.

117 Results

118 We studied a previously described and well-characterized cohort of young adult CF patients aged 119 18 to 22 with chronic Pa infection (Acosta, Heirali et al. 2018). Using Pa SNV frequencies 120 quantified by AmpliSeq in patient sputum, we sought to predict two measures of lung disease 121 severity: (1) baseline lung function (FEVp score) at the time of sputum sample collection, 122 classified as severe or mild, and (2) relative lung function decline in the following five years, 123 classified as rapid or non-rapid. After filtering for AmpliSeq sequencing quality, we excluded 10 124 patients with low coverage of Pa, leaving 54 patients for further analysis (Methods). The clinical 125 and demographic characteristics of the final cohort are summarized in Table 1, and the excluded 126 patients were not apparent outliers in their clinical profiles (data not shown). From the filtered 127 sequence data we identified SNVs within the 209 genes represented in the AmpliSeq panel, and 128 estimated the frequency of each SNV within each patient sputum sample. In total across the 54 129 patient samples, we identified 7,867 synonymous and 4,452 non-synonymous SNVs 130 (Supplementary Data 2). All variants were used for population stratification analysis and only non-131 synonymous SNVs were used for training ML models.

132

133 Stratification in the *Pa* population

134 We first quantified the extent of *Pa* population stratification, which can be problematic if there are 135 genetic structures (e.g. clonally-related clusters or strains) that can be confounded with the lung disease outcomes of interest. If a particular genetic cluster or lineage is associated with worsened 136 137 lung disease, it then becomes difficult to pinpoint the most likely SNVs associated with the disease 138 outcome because all mutations (whether related to disease or not) in a cluster are correlated. We 139 know a priori based on pulsed-field gel electrophoresis (PFGE) typing that our dataset contains a 140 highly prevalent lineage of *Pa* (called Prairie Epidemic Strain or PES; sequence type (ST)-192; 141 **Table 1)** suspected to be associated with disproportionate lung disease (Somayaji, Lam et al. 142 2017). We confirmed this by hierarchical clustering of the Pa AmpliSeq data (n=12,319 SNVs, 143 including both synonymous and non-synonymous variants), which revealed two apparent genetic 144 clusters (Fig. 1a), one of which was strongly associated with the PES lineage (Fisher exact test, odds ratio=168.0, P = 1.1e-09; Fig. 1b). The observed Pa genetic clusters are also weakly 145 146 associated with the birth cohort (Chi square test, P = 0.0095) which is likely due to unequal 147 prevalence of PES across birth cohorts (Supplementary table S1). No other clinical factor was

significantly associated with either genetic cluster (Fig. 1b). Importantly, neither cluster is correlated with either baseline lung function (Fisher exact test, p-value: 0.81) or lung function decline (Fisher exact test, p-value: 0.51) (Fig. 1b), indicating that these outcomes are unlikely to be confounded by Pa population stratification, and finer-grained predictive modeling is warranted. We also noted that lung disease progression over 5 years (lung function decline) is not significantly correlated with baseline lung function at sample collection (Fig. 1a).

154



157 Figure 1. The *Pa* population is stratified into two genetic clusters, neither of which is associated with
158 baseline lung function (FEVp) or lung function decline.

- (A) Heatmap showing correlations in SNV frequencies between pairs of sputum samples. Strong correlations are yellow; weak correlations in blue. Rows and columns (samples) are ordered by hierarchical clustering. Distribution of baseline lung function measured by FEVp score (27 Severe and 27 Mild individuals), lung function decline (23 Rapid and 31 Non-rapid individuals) and PFGE typing (25 PES and 29 Unique) are presented on the y axis. Baseline lung function and lung function decline over five years are not significantly correlated (Pearson R² score=-0.19, p-value=0.22).
- 165(B) P-values for the association between clinical data and genetic clusters are determined by t-test for166numerical data and chi-square test for categorical data (Methods). Only the association between167PFGE type (PES or non-PES) is significantly associated with the genetic clusters in panel A (P <1680.0045 after Bonferroni correction for multiple tests).

169 Genetic and clinical features associated with baseline lung function and lung function decline in CF

170 patients

171 A common challenge in predicting outcomes from sequence data is the sparsity of the data, that is, 172 relatively few available samples compared to the large number of genetic markers (called 173 "features" in ML context). To address this problem, feature selection has been used to remove 174 non-informative features (i.e., SNVs and clinical factors) and focus only on the most predictive 175 ones (Mobegi, Cremers et al. 2017, Recker, Laabei et al. 2017, Méric, Mageiros et al. 2018, 176 Macesic, Don't Walk et al. 2020). We used an ensemble gradient boosting technique for feature 177 selection (Methods). Out of 4,452 non-synonymous SNVs and eleven clinical factors considered, 178 our model selected only 34 SNVs (hereafter called predictor SNVs) and three clinical factors (age, 179 BMI and Pa abundance) that account for 99% of the cumulative feature importance (Fig. 2). This 180 means that a minimal set of SNVs and clinical factors provides 99% of the information used in 181 predicting baseline lung function at the time of sampling (Fig. 2a). An equivalent analysis for lung 182 function decline after five years identified 33 predictor SNVs and the same three clinical factors 183 that contributed to 99% of the cumulative feature importance (Fig. 2b). For both baseline lung 184 function and future lung function decline, the phenotype is not simply predicted based on the 185 presence/absence of each SNV, but rather on more subtle information about SNV allele 186 frequencies within patients. In other words, predictive SNVs occur at a range of frequencies, rather 187 than being clustered mainly around 0 or 1 (Supplementary fig. 1).



Figure 2. *Pa* genes and clinical factors selected as top predictive features of baseline lung function and lung function decline. Normalized importance of genomic and clinical data that contribute to 99% cumulative relative importance for prediction of (A) baseline lung function at time of sample collection and (B) risk of 5-year progression (lung function decline). On the y-axis, gene identifiers (locus tag|chromosome location based on PES genome) are color-coded based on their functional classification and named genes are shown on the right, when available.

196

197 The three selected clinical factors associated with both baseline lung function and lung function 198 decline are body mass index (BMI), Pa relative abundance (from 16S rRNA gene amplicon 199 sequence data from a previous study of the same cohort; (Acosta, Heirali et al. 2018), and age (Fig. 200 2). Multiple studies have shown an association between poor lung function and low BMI (Snell, 201 Bennetts et al. 1998, Cystic Fibrosis Foundation 2006, Kumru, Emiralioğlu et al. 2018), high 202 abundance of Pa (Cox, Allgaier et al. 2010) and age (Zhao, Hao et al. 2020, Cox, Allgaier et al. 203 2010). As expected, Pa relative abundance also showed a strong negative correlation with Shannon 204 and Simpson microbiome diversity indices (Supplementary fig. 2), indicating that Pa abundance 205 can be considered as a proxy for lung microbiome diversity in our dataset. However, Shannon and 206 Simpson diversity indices were not selected as predictive features in our model, consistent with a 207 previous work (Acosta et al. 2018; Zhao, Hao et al. 2020). This suggests that, even if low 208 microbiome diversity indices are associated with CF disease progression, the low diversity is likely 209 driven by the dominance of key pathogens such as Pa. By identifying previously known clinical 210 determinants of the lung function in CF patients, these results provide validation for the ensemble 211 gradient boosting approach to feature selection.

212

213 To interpret the possible roles of Pa SNVs in CF lung disease, we classified the known or predicted 214 function of genes containing predictor SNVs (hereafter called predictor genes) into functional 215 categories manually curated based on existing literature. The predictor SNVs with the highest 216 weighted importance for both baseline lung function and future lung function decline outcomes 217 are located within genes that play a role in seven functional categories (Table 2). The distribution 218 of predictor genes is generally similar to the distribution of gene functions included in the 219 AmpliSeq panel (Supplementary fig. 3). However, the predictor genes for baseline lung function 220 are enriched in iron transport and metabolism (13.4% in baseline lung function predictor genes vs. 221 1.4% in the AmpliSeq panel, P = 0.00018; Supplementary fig. 3). The genes encoding the ferric 222 enterobactin receptor (PirA) and the ferrichrome receptor (FiuA) respectively account for 8.9%

223 and 3.7% of the total normalized importance for baseline lung function (Fig. 2a), and *pirA* contains 224 multiple predictor SNVs (Fig. 3a). In contrast, the predictor genes for lung function decline are 225 enriched in stress/metabolism (33.6 % in lung function decline predictor genes vs. 13.4% in the 226 AmpliSeq panel, P = 0.002; Supplementary fig. 3). Notably, the hypothetical protein PA1874 227 accounts for 16.9% of the total normalized importance for lung function decline prediction and 228 includes 7 out of 33 predictor SNVs (Fig. 2b, Fig. 3b), as well as two predictor SNVs for baseline 229 lung function (Fig. 3a). This hypothetical protein has also been shown to play a role in resistance 230 of Pa to multiple antibiotics (Zhang and Mah 2008). The PA4937 gene, which encodes an RNase 231 R exoribonuclease involved in stress/metabolism, is also a predictor of both baseline lung function 232 and subsequent lung function decline, with multiple predictor SNVs (Fig. 2a, Fig. 3a). The two 233 genes PA0861 (rbda) and PA4601 (morA), which encode regulators of genes involved in the 234 bacterial cell wall, LPS, capsule, motility and attachment, are also among the important predictor 235 genes for both baseline lung function and lung function decline (Fig. 2).





245 Predicting lung disease severity and progression in individuals with CF using genetic and clinical factors

246 Having identified Pa SNVs predictive of disease outcomes, we evaluated their predictive 247 performance using the area under receiver operating characteristic (AUROC) curve and other 248 standard metrics (Methods). A genetic programming algorithm identified logistic regression as the 249 best predictive model for both baseline lung function and lung function decline. To confirm this 250 result, we compared the performance of logistic regression with three other common ML 251 algorithms including support vector machines (SVM), random forests, and extreme gradient 252 boosting (XGBoost). It should be noted that while we used an ensemble LGBM model (Methods) 253 for feature selection, we did not use it for predictive modeling to avoid overfitting (*i.e.* to confirm 254 that our feature selection method is not biased toward selecting features that could be used only by 255 one specific ML model). Logistic regression had the best predictive performance for both 256 phenotypes (Table 3, Fig. 4). Specifically, cross-validation (Methods) showed that logistic 257 regression was the most accurate and precise model for both baseline lung function, with an 258 average AUROC score of 0.87 (95% CI, 0.84-0.90), and for lung function decline, with a score of 259 0.74 (95% CI: 0.71-0.78; Table 3, Supplementary table 2). Linear logistic regression is a simple 260 classification model that makes it reasonably robust against overfitting (Kuhn and Johnson 2013). 261 The second-best method was SVM, also a linear model (Supplementary table 2). Across all 262 models, the baseline lung function phenotype was more accurately predicted than lung function 263 decline, consistent with predictions becoming more uncertain further into the future (Table 3, 264 Supplementary table 2). Importantly, all models could predict both phenotypes significantly 265 better than expected by chance (compared to a permutation test using data with shuffled outcome 266 labels; Fig. 4a, c, Supplementary fig. 4).



268 269 Figure 4. Predictive models of baseline lung function and lung function decline perform significantly 270 better than expected by chance.

271 (A) Classification score of baseline lung function using logistic regression (green dashed line) is 272 significantly higher than expected based on permuted data (mean shown in black dashed line).

273

(B) Average AUROC scores of different ML models to predict baseline lung function, compared to chance (permuted sample labels). Shading indicates the 95% confidence interval. 274

275 (C) Classification score of lung function decline using logistic regression compared to permuted data.

- 276 (D) Average AUROC scores for lung function decline prediction.
- 277

278 Clinical factors have been traditionally used to predict lung disease progression in CF patients 279 (Alaa and van der Schaar 2018). We therefore assessed if integrating clinical factors could improve 280 upon the predictions based on Pa AmpliSeq data alone. The three clinical factors (BMI, Pa 281 abundance and age) identified by our feature selection approach are previously recognized as 282 factors affecting lung function in CF patients. Including these three clinical factors in our 283 predictive models led to modest (~5% increase in AUROC) performance increases for both 284 baseline lung function and lung function decline outcomes across the four ML models (Table 4, 285 Supplementary table 2). We conclude that, while these clinical factors are useful, most of the 286 predictive power comes from the *Pa* genetic data.

287

288 Lack of generalizability is one of the main limiting factors for the translation of prediction models 289 into clinically useful diagnostics. Machine learning models often have low generalizability (i.e. 290 "overfit") in scenarios where the model performs well on the dataset used to train the model, but 291 fails to achieve similar prediction accuracy on new data. We plotted learning curves to assess how 292 logistic regression predictions improved by training on more data (Raschka 2018). We found that 293 the performance difference between training and testing data decreases as sample size increases 294 (Supplementary Figure 5). There were no major differences in prediction accuracy of training 295 and testing datasets (Supplementary Figure 5) which suggests the model does not suffer from 296 significant overfitting. We also noted that cross validation scores for both baseline lung function 297 and lung function decline models continued to increase for the testing dataset as more data was 298 used for model training (Supplementary Figure 5) which suggests the model could be further 299 improved with more data.

300

301 Discussion

302 Considering the critical role of Pa in CF-related morbidity and mortality, here we established a 303 link between Pa genetic diversity and lung disease severity in a cohort of CF young adults with 304 chronic Pa infections. Despite a modest sample size, our study provides a proof of principle 305 demonstrating the utility of ML models for predictive modeling of lung function severity and 306 decline in CF patients using bacterial genetic and clinical data. Although our models do not appear 307 to be severely overfit, fully validating their predictive performance will require independent 308 cohorts. We also identified potential genetic biomarkers associated with lung disease severity. 309 Overall, our findings provide evidence that ML models can identify CF individuals at high-risk 310 for poor Pa infection outcomes using Pa genetic data.

311

Our work is based on a subset of samples from a previously described cohort study that identified dominance of *Pa* in the sputum microbiome (and the resulting reduction of community diversity) as a predictor of lung function decline in a cohort of young CF adults (Acosta, Heirali et al. 2018). Here we focused on a subset of patients with a lung microbiome dominated by *Pa*. While these patients are already at increased risk of lung disease, we found that the severity of disease at the

317 time of sampling and five years into the future could be predicted based on genetic variation within 318 the infecting Pa population. Even within this patient cohort in which Pa was present, we replicated 319 the finding that Pa relative abundance is associated with disease severity and progression -320 although it is a less important biomarker than many SNVs within the Pa genome. This suggests 321 that genetic variation in dominant pathogens can significantly complement and improve upon 322 predictions of disease status based on the microbiome. Along these lines, another recent study 323 showed that the Pa genomic data can predict pathogenicity in mouse models (Pincus, Ozer et al. 324 2020).

325

326 We recognize that, in addition to variation in the host genome, the polymicrobial community 327 inhabiting the CF lung has been identified as an important modifier of disease progression. 328 Numerous studies of the lung microbiome have shown an association between decreasing 329 microbial community diversity and worsening lung function (Cox, Allgaier et al. 2010, van der 330 Gast, Flight, Smith et al. 2015, Zhao, Schloss et al. 2012, Coburn, Wang et al. 2015, Cuthbertson, 331 Walker et al. 2020), as well as progression to end-stage lung disease (Acosta, Heirali et al. 2018). 332 However, microbiome diversity may have limited predictive value as there is high interpersonal 333 variability in lung microbiomes (Cuthbertson, Walker et al. 2020), and a large number of adult CF 334 individuals have microbiomes dominated by pathogens such as Pa. Zhao, Hao et al. (2020) also 335 recently showed that microbiome composition data does not improve machine learning (ML) 336 prediction performance compared with using only clinical factors. Our results suggest that genetic 337 diversity within key pathogens like Pa could complement or even supersede microbiome 338 community diversity for predicting clinical outcomes in specific patient subsets.

339

340 Limitations of our study include a relatively small sample size of patients (N=54) from a single 341 cohort, and a relatively small number of targeted genes (N=209) included in the AmpliSeq panel. 342 As such, we consider our work a proof of concept that could be improved upon in larger cohorts 343 and by including more loci in the Pa genome. Indeed, learning curves showed that predictive 344 accuracy is likely to improve with more samples. Although we performed cross-validation by 345 subsampling our 54 patients for model training and testing, the model should ideally be tested on 346 a completely independent cohort to assess its real-world predictive value. Despite these limitations, 347 the models made significantly better predictions than expected by chance. As expected, predicting

348 lung function decline five years into the future proved more challenging than doing so at the time 349 of sampling. Still, our results provide a key first step toward clinical diagnostics of patients most 350 at risk of lung function decline.

351

352 As with any genotype-phenotype association method, our approach does not fully guarantee causal 353 relationships, and rather provides candidate genes for further experimental testing. Our study is 354 further complicated by the fact that the phenotypes of interest (i.e., baseline lung function and 355 future lung function decline) are complex host phenotypes, while the genotype data comes from 356 only *Pa*. It is therefore unclear to what extent *Pa* SNVs play a causal role in lung function decline, 357 or merely serve as useful biomarkers. Regardless, we were able to pinpoint SNVs in several genes 358 of interest. This was feasible because the strong population stratification of Pa into PES and non-359 PES lineages was fortunately not associated with the disease outcomes of interest. This allowed 360 us to identify SNVs in several genes that provided independent biomarkers of disease.

361

362 Several candidate genes containing SNVs predictive of disease status and progression were 363 identified as targets for further investigation. We note that genes in the AmpliSeq panel were 364 selected *a priori* for their known involvement in virulence, disease progression, or within-patient 365 evolution. However, it was not known *a priori* which, if any, of these genes would contains SNVs 366 predictive of lung function or decline. For example, we found that baseline lung function predictor 367 SNVs are enriched in genes involved in iron transport and metabolism. The AmpliSeq panel only 368 included three iron-related genes, of which two (pirA and fiuA) contained SNVs associated with 369 baseline lung function. Updated AmpliSeq panels or whole-genome sequencing, along with 370 targeted experimental studies, could be used to test the hypothesis that variation in these genes 371 plays a role in disease progression. Multiple studies have shown competition for iron to be key for 372 the survival and virulence of many of the pathogens that reside in the CF lung, including Pa 373 (Bouvier 2016, Firoz, Haris et al. 2021). We also found that SNVs predictive of lung function 374 decline are enriched in genes involved in stress/metabolism. Notably, the gene PA1874 includes 375 seven predictor SNVs comprising 16.9% of total feature importance for lung function decline, and 376 two predictor SNVs for baseline lung function prediction, suggesting its general importance in 377 disease severity and progression in CF patients. PA1874 encodes a multidrug efflux pump 378 involved in biofilm-dependent resistance to antibiotics including tobramycin, gentamicin, and

ciprofloxacin (Zhang and Mah 2008; Poudyal and Sauer 2018), and could be a potentially
 promising biomarker of CF disease severity, which merits further investigation.

381

382 Among the set of clinical factors studied, BMI, Pa abundance, and age were identified as important 383 predictors of both baseline lung function and lung function decline. These are all known risk 384 factors for CF disease severity and progression (Acosta et al. 2018, Snell, Bennetts et al. 1998, 385 Kumru, Emiralioğlu et al. 2018, Cox, Allgaier et al. 2010, Zhao, Hao et al. 2020). By including 386 these features in our prediction models, we noted a moderate increase across all the measured 387 metrics relative to using only AmpliSeq data. These results are in line with previous studies 388 showing the improvement of ML-based phenotype prediction by adding relevant clinical data 389 (MacFadden, Melano et al. 2019, Pincus, Ozer et al. 2020). We note that clinical factors only 390 modestly improved the performance of the models (\sim 5%), highlighting the rich information and 391 predictive value of the *Pa* AmpliSeq data alone.

392

In summary, our study demonstrates that SNVs in the *Pa* genome, assayed with an AmliSeq panel and identified by ML models, can be powerful predictors of lung disease severity and progression in CF patients with chronic *Pa* infections. Even though this disease outcome is affected by multiple microbial, host genetic and environmental factors, *Pa* SNVs add complementary predictive value. With additional genetic and clinical data, our ML model could be further fine-tuned and eventually used as a biomarker to preemptively identify individuals with CF at high-risk for more aggressive observation and treatment.

400

401 Materials and methods

402 Patient selection, sample and clinical data collection

The Calgary biobank includes frozen whole sputum samples prospectively collected from individuals with CF followed at the Calgary Adult CF clinic from 1998 to 2017, as described previously (Acosta, Heirali et al. 2018, Acosta, Whelan et al. 2017). A cohort of 104 individuals between the ages of 18 and 22 with sputum available from the Calgary biobank was previously characterized (Acosta, Heirali et al. 2018). For this study, we selected from this cohort all individuals with sputum cultures positive for *Pa* (64 out of 104 patients). Out of these 64 samples, 54 yielded AmpliSeq data of sufficient depth (>10X average depth of coverage of the targeted

410 genes) and were retained for further analysis. Clinical data collected for each patient is outlined in 411 **Tables 1** and **S1** and includes age, gender, body mass index, CFTR genotype, birth cohorts, and 412 microbiology (mucoid phenotype, Pa relative abundance, microbiome diversity indices). The 413 study was carried out with the approval from the Research Ethics Boards from the University of

- 414 Calgary (15-0854) and McGill University Health Centre (15-623).
- 415

416 As a measure of lung disease severity at the time of sputum collection, we used the spirometric 417 measure of forced expiratory volume in one second, percent predicted (hereafter referred to as 418 'baseline lung function' and noted FEVp) a standard measure of lung function normalized for age, 419 height, and self-identified gender and ethnicity. Baseline lung function was categorized as severe 420 for FEVp < 60%, and mild for FEVp $\ge 60\%$. Long-term lung function decline (hereafter noted as 421 'lung function decline') was measured using the relative rate of FEVp decline (determined by 422 subject-specific constructed linear regressions over the 5 years following sputum collection as 423 described in Acosta, Heirali et al. (2018). Lung function decline was categorized as 'rapid' when 424 the 5-year FEVp decline was >5%, and 'non-rapid' when less than or equal to 5%.

425

426 Sputum DNA extraction and microbiome analyses

427 Genomic DNA was extracted from a single biobanked sputum sample per patient as previously 428 described (Acosta, Heirali et al. 2018), and used as template for 16S rRNA gene amplicon and Ion 429 AmpliSeq sequencing. The Prairie Epidemic Strain (PES) genotype, a highly prevalent strain in 430 our study population, was identified by pulse field gel electrophoresis (PFGE) and/or multi-locus 431 sequence typing (MLST) (Parkins, Glezerson et al. 2014). For microbiome analysis, bacterial 432 communities in CF sputum and reagent blanks were characterized by amplification and sequencing 433 the V3-V4 region of the 16S rRNA gene, as previously described (Acosta, Heirali et al. 2018). The 434 sequencing reads were then processed to identify operational taxonomic units (OTUs) (Acosta, 435 Whelan et al. 2017). Relative Pa abundance was determined as the proportion of Pseudomonas 436 reads relative to the total 16S reads.

437

438 Ion AmpliSeq panel design and sequencing

439 The AmpliSeq panel targeted 209 *Pa* genes previously implicated in pathogenicity, antimicrobial

440 resistance and within-host pathoadaptation during chronic infection (Supplementary Data 1). The

441 AmpliSeq primer panel (generated by Life Technologies, Carlsbad, CA, U.S.A.) was designed by 442 the AmpliSeq Custom Services (White Glove, Thermo Fisher Scientific) to provide high 443 sequencing coverage of the target genes based on the Pa PAO1 genome (NCBI accession number: 444 GCA 000006765.1), with 100% breadth of coverage for 205 genes and >96% in 4 genes, based 445 on the tiling of amplicons. Four additional genome assemblies of Pa clinical isolates 446 (GCF 004375495.1, GCF 004374685.1, GCF 004374275.1 and the PES genome (NCBI 447 BioProject: PRJNA750451) were also evaluated along with PAO1 for the optimization of primer 448 design, tiling and pooling to achieve maximal target coverage by the primer panel with minimal 449 misalignments and homology with the human genome.

AmpliSeq libraries were constructed using the Ion AmpliSeqTM Library kit 2.0 and IonCodeTM barcode set with the following modifications. SparQ magnetic beads (Quantabio) were used for purification, and individual libraries were quantified using the Quant-iTTM PicoGreenTM dsDNA Assay Kit (ThermoFisher). Samples were mixed in equimolar proportions and the pooled library (200 pM) was loaded on an Ion Chef for template preparation using HiQ reagents. The P1 v3 chips were sequenced using an Ion Proton sequencer (500 flows) with P1 HiQ sequencing reagents following manufacturer's instructions.

457 AmpliSeq variant calling

458 The quality of AmpliSeq sequencing was confirmed using TorrentSuite[™] software (v.5.2, Thermo 459 Fisher Scientific Inc.). Raw sequencing reads were trimmed based on per-base phred quality score 460 cutoff ('q' flag) of 18, window size of 1 base pair and minimum remaining sequence length ('l' 461 flag) of 19 using fastq-mcf (v.1.04.636) (Aronesty 2013). Reads were aligned to the PES genome 462 (CP080405) using BWA MEM (Li, 2013), and the alignments were sorted and indexed using 463 SAMtools (v.1.9) (Li, Handsaker et al. 2009). Samples with average sequencing depth $\leq 10X$ 464 across the target genes were discarded, leaving 54 samples for further analysis. Single-nucleotide 465 variants (SNVs) with minimum mapping quality of 20, minimum base quality of 18 and minimum 466 coverage of 10x were then identified using VarScan 2 (Koboldt, Zhang et al. 2012) and functional 467 consequences of each SNV were inferred using snpEFF (v.2.4.2) (Cingolani, Platts et al. 2012). 468 The SNV allele frequencies (ranging from 0 to 1) at each polymorphic site covered by the 469 AmpliSeq panel were used to generate a SNV frequency matrix, with samples as rows and 470 nucleotide positions as columns. For baseline lung function (measured based on FEVp score) and

471 lung function decline (disease progression) prediction analysis, all synonymous variants were 472 filtered out and only non-synonymous variants (including nonsense and missense mutations, 473 frameshift deletions and insertions) were used (Supplementary Data 2). All SNVs (including 474 synonymous sites) were included for population stratification analyses.

475

476 Bacterial population stratification

477 Population stratification in Pa was evaluated by calculating pairwise Pearson correlation 478 coefficients between sputum samples based on the SNV frequency matrix followed by 479 determination of distinct genome subgroups using hierarchical agglomerative clustering 480 implemented in SciPy (Virtanen, Gommers et al. 2020) and visualized using the python seaborn 481 package (Waskom, Botvinnik et al. 2017). This identified two major subclusters of Pa, one of 482 which was significantly enriched in PES strains. To determine if any clinical factors were 483 associated with these subclusters, we used t-tests for continuous variables including age, body 484 mass index (BMI), Shannon and Simpson diversity indices and Pa abundance in the sputum 485 sample. For binary variables including PFGE typing (PES or not), gender, host CFTR genotype, 486 death, mucoid presence/absence status, baseline lung function and lung disease progression (lung 487 function decline), we used a Fisher Exact Test. A Chi-square test was used for the multi-categorical 488 birth cohort factor.

489

490 Feature selection

491 In a machine learning context, a feature is defined as an individual measurable characteristic of an 492 observed phenomenon. In this study, the features considered are *Pa* genetic variants (SNV 493 frequencies) identified by the AmpliSeq panel and the clinical factors linked to the study patients 494 (Supplementary table 1). In order to reduce the high-dimensionality of the dataset (i.e. high ratio 495 of features to sample size), a feature selection approach was applied using feature-selector v1.0.0 496 (Koehrsen 2019). Briefly, 50 rounds of a gradient boosting ensemble method implemented in 497 LightGBM (Ke, Meng et al. 2017) were conducted on the training dataset sampled by a bootstrap 498 approach (43 samples in training set and 11 in test set in each bootstrap). The feature importance 499 (i.e. scores assigned to each input feature indicating the relative importance of the feature when 500 making a prediction) were averaged over the 50 bootstraps. The set of features required to obtain 501 99% cumulative relative importance were kept to perform prediction analysis and the remaining

features were discarded. The enrichment of predictor SNVs across functional gene categories relative to the total genes in the AmpliSeq panel were measured using a Fisher exact test with a

- family-wise error rate of 0.05 adjusted for multiple testing using Bonferroni method.
- 505

506 Training predictive model of lung function

507 The selected SNVs and clinical features were then used to train independent prediction models for 508 baseline lung function and disease progression (lung function decline) in the CF patient cohort. To 509 identify the best prediction model, a genetic programming algorithm implemented in TPOT (Le, 510 Fu et al. 2019) was used. TPOT attempts to identify the machine learning prediction pipeline with 511 the best performance (i.e. cross-validation using the area under the receiver operating characteristic 512 curve (AUROC) as the performance metric). We began with 10,000 random prediction pipelines 513 which were evolved over 5 generations with an offspring size of 100 in each generation, using the 514 recommended mutation rate of 0.9 and recombination rate of 0.1. The performance of each pipeline 515 was evaluated using 20-fold stratified shuffled cross validation. This analysis revealed logistic 516 regression with L2 regularization to be the most generalizable prediction model based on the cross-517 validation scores. To confirm the results of genetic programming, three additional methods 518 including extreme gradient boosting implemented in XGBoost (Chen and Guestrin 2016), 519 ensemble decision trees implemented in random forest (Svetnik, Liaw et al. 2003) and linear 520 support vector machine (SVM) with linear kernel were also tested, using 20-fold stratified shuffled 521 cross validation implemented in scikit-learn (Pedregosa, Varoquaux et al. 2011). The performance 522 of machine learning models were evaluated using six metrics including AUROC, accuracy 523 (number of correct predictions/total number of predictions), precision (True Positives / (True 524 Positives + False Positives)), recall (True Positives / (True Positives + False Negatives)), F1 score 525 (2*(Precision*Recall)/Precision+Recall), and balanced accuracy (bACC), the average of recall 526 obtained on each class (i.e. severe/mild for baseline lung function and rapid/non-rapid for lung 527 function decline).

528

529 To evaluate the statistical significance of the prediction performances (AUROC scores) obtained 530 by ML models in comparison with random expectations, a non-parametric permutation test 531 (Pedregosa, Varoquaux et al. 2011) was performed using 20-fold stratified shuffled cross-

validation across hundred rounds of label switching and model training followed by empirical *p*-

- 533 value estimation (i.e. the chance that the observed AUROC scores obtained using the data could
- 534 be obtained by chance alone).
- 535

536 Data availability

- 537 All amplicon sequencing data generating in this project are deposited in NCBI GenBank under
- 538 BioProject PRJNA763719.
- 539

540 Acknowledgements

- 541 The project was supported by funding from CIHR (PJT-148827 to DN) and a Vertex Research
- 542 Innovation Award (DN), and salary support from the Cystic Fibrosis Canada Research
- 543 Fellowship (Award ID 558850 to JD), the Leopoldina Foundation (German National Academy
- of Sciences Leopoldina, Award ID LPDS 2017-17), the Reseau en Santé respiratoire (IL), and
- 545 the Fonds de Recherche en Santé Quebec (IL, DN). MMS and BJS were supported by a Genome
- 546 Canada and Genome Quebec Bioinformatics and Computational Biology grant.
- 547 We would like to acknowledge Michael Surette for providing the PES genome sequence and
- 548 Pradeep K. Singh for input in the Ampliseq design.

549 Tables

550

551 **Table 1. Patient clinical data.**

	Baseline lung function				Lung function decline over 5 years			
Patient data	Severe (n=27)	Mild (n=27)	Test statistic	<i>P</i> value	Non-rapid (n=31)	Rapid (n=23)	Test statistic	<i>P</i> value
<i>Pa</i> relative abundance	0.59 (0.32)	0.35 (0.32)	2.48	0.01	0.46 (0.33)	0.49 (0.32)	0.3	0.75
Age (year)	19.05 (1.13)	19.37 (1.16)	1.40	0.16	19.21 (1.1)	19.22 (1.25)	0.24	0.80
Body Mass Index (kg/m²)	19.01 (2.3)	21.45 (2.3)	3.45	0.0005	20.62 (2.9)	19.70 (2.1)	1.18	0.23
Shannon index	1.12 (0.64)	1.21 (0.68)	0.42	0.66	1.31 (0.66)	1.06 (0.65)	1.44	0.24
Simpson index	0.48 (0.26)	0.5 (0.28)	0.23	0.81	0.54 (0.26)	0.45 (0.27)	1.61	0.20
PES (PFGE typing)	15	9	2.5	0.17	16	8	2.0	0.27
Homozygous ΔF508	15	13	1.34	0.78	14	14	0.52	0.28
Not-deceased (Death)	22	25	0.35	0.42	27	20	1.01	1
Male (Gender)	11	9	0.72	0.77	8	12	3.13	0.86
Mucoid	24	23	0.71	1	27	20	0.98	1
Birth cohort 1978- 1984	11	8	0.47	0.49	12	7	1.31	0.25
Birth cohort 1985- 1990	9	11	0.2	0.65	7	13	1.8	0.17

⁵⁵²

553 Values show the mean or absolute count, with standard deviation in parenthesis where applicable.

554 Baseline lung function is defined as severe when FEVp < 60 and mild otherwise. Lung function

555 decline is defined as non-rapid when five-year FEVp decline < 5% and rapid otherwise. The

556 relative abundance of *Pa*, as well as Shannon and Simpson diversity indices, were computed based

- 557 on 16S rRNA gene sequencing of the lung microbiome community. Homozygous Δ F508 indicates
- 558 the counts of individuals with a Δ F508/ Δ F508 genotypes; others include heterozygotes or other
- 559 genotypes. Test statistics are Wilcoxon rank-sum statistic for numerical data (Pa, Age, BMI,
- 560 Shannon and Simpson indices) and odds ratio for categorical data.

561 Table 2. Functional classification of predictor genes used for prediction of baseline lung

562 function and lung function decline.

	Baseline lung function predictor genes	Lung function decline predictor genes	Shared genes
Host adaptation	PA0454 conserved hypothetical protein PA1188 hypothetical protein PA2077 oleate 10S-lipoxygenase PA3234 probable sodium:solute symporter PA3327 probable non-ribosomal peptide synthetase PA3728 hypothetical protein PA3895 probable transcriptional regulator PA4311 conserved hypothetical protein PA4489 magD PA4735 hypothetical protein PA4961 hypothetical protein	PA2072 conserved hypothetical protein PA2151 conserved hypothetical protein PA2435 probable cation- transporting P-type ATPase PA2635 hypothetical protein PA3105 xcpQ PA4372 hypothetical protein	PA4719 probable transporter PA5238 probable O-antigen acetylase
Antibiotic resistance	PA2018 <i>mexY</i> PA3168 <i>gyrA</i>	PA4020 <i>mpl</i> PA4082 <i>cupB5</i> PA4266 fusA1	
Cell wall, LPS, capsule, motility & attachment	PA1099 <i>fleR</i>	PA0705 <i>migA</i> PA3703 <i>wspF</i> PA4082 <i>cupB5</i>	PA0861 <i>rbdA</i> PA4601 <i>morA</i>
Iron transport and metabolism	PA0470 <i>fiuA</i> PA0931 <i>pirA</i>		
Regulators			PA0600 <i>agtS</i>
Stress/ metabolism		PA1259 <i>lhpH</i> PA4814 <i>fadH</i> 2	PA1874 <i>hypothetical protein</i> PA4937 <i>rnr</i> PA5060 <i>phaF</i>
Virulence	PA4211 <i>phzB1</i> PA5266 <i>vgr</i> G6	PA0934 <i>relA</i> PA2361 <i>icmF3</i> PA3290 <i>tle1</i> PA5262 <i>fimS</i>	

564 Table 3. Performance of logistic regression in predicting baseline lung function and lung

565 function decline using genomic data only, or a combination of genomic and clinical data.

566 See Methods for descriptions of the performance metrics.

567

		Genomic data (95% Cl)	Genomic and clinical data (95% Cl)
	AUROC	0.87 (0.84, 0.9)	0.92 (0.84, 1.00)
	bACC	0.81 (0.78, 0.84)	0.83 (0.72, 0.94)
Baseline	Accuracy	0.81 (0.78, 0.84)	0.83 (0.72, 0.94)
lung function	F1	0.81 (0.78, 0.83)	0.83 (0.72, 0.94)
	Precision	0.83 (0.81, 0.86)	0.84 (0.73, 0.94)
	Recall	0.81 (0.78, 0.84)	0.83 (0.72, 0.94)
-	AUROC	0.74 (0.71, 0.78)	0.79 (0.70, 0.88)
	bACC	0.63 (0.59, 0.66)	0.66 (0.59, 0.74)
Lung	Accuracy	0.64 (0.60, 0.67)	0.67 (0.60, 0.75)
decline	F1	0.62 (0.58, 0.65)	0.66 (0.58, 0.74)
	Precision	0.65 (0.61, 0.69)	0.69 (0.60, 0.78)
	Recall	0.64 (0.60, 0.67)	0.67 (0.60, 0.75)

569 Bibliography

Acosta, N., A. Heirali, R. Somayaji, M. G. Surette, M. L. Workentine, C. D. Sibley, H. R. Rabin and M. D. 570

- 571 Parkins (2018). "Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic 572 fibrosis." <u>Thorax</u> 73(11): 1016-1025.
- 573 Acosta, N., F. J. Whelan, R. Somayaji, A. Poonja, M. G. Surette, H. R. Rabin and M. D. Parkins (2017).
- 574 "The evolving cystic fibrosis microbiome: a comparative cohort study spanning 16 years." Annals of the 575 American Thoracic Society, 14(8): 1288-1297.
- 576

577 Alaa, A. M., & van der Schaar, M. (2018). Prognostication and risk factors for cystic fibrosis via automated 578 machine learning. Scientific reports, 8(1), 1-19.

- 579
- 580 Aronesty, E. (2013). Fastq-mcf: sequence quality filter, clipping and processor.
- 581 Bouvier, N. M. (2016). Cystic fibrosis and the war for iron at the host-pathogen battlefront. Proceedings of 582 the National Academy of Sciences, 113(6), 1480-1482.
- 583

584 Bragonzi, A., M. Paroni, A. Nonis, N. Cramer, S. Montanari, J. Rejman, C. Di Serio, G. Döring and B. 585 Tümmler (2009). "Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes 586 clones with adapted virulence." American journal of respiratory and critical care medicine 180(2): 138-145.

587

588 Chen, T., & Guestrin, C. (2016, August). Xgboost: A scalable tree boosting system. In Proceedings of the 589 22nd acm sigkdd international conference on knowledge discovery and data mining (pp. 785-794). 590

- 591 Cingolani, P., A. Platts, L. L. Wang, M. Coon, T. Nguyen, L. Wang, S. J. Land, X. Lu and D. M. Ruden 592 (2012). "A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: 593 SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3." Fly 6(2): 80-92. 594
- 595 Coburn, B., P. W. Wang, J. D. Caballero, S. T. Clark, V. Brahma, S. Donaldson, Y. Zhang, A. Surendra, 596 Y. Gong and D. E. Tullis (2015). "Lung microbiota across age and disease stage in cystic fibrosis." 597 Scientific reports 5(1): 1-12. 598
- 599 Cox, M. J., M. Allgaier, B. Taylor, M. S. Baek, Y. J. Huang, R. A. Daly, U. Karaoz, G. L. Andersen, R. 600 Brown and K. E. Fujimura (2010). "Airway microbiota and pathogen abundance in age-stratified cystic 601 fibrosis patients." PloS one 5(6): e11044.
- 602

603 Cuthbertson, L., A. W. Walker, A. E. Oliver, G. B. Rogers, D. W. Rivett, T. H. Hampton, A. Ashare, J. S. 604 Elborn, A. De Sovza and M. P. Carroll (2020). "Lung function and microbiota diversity in cystic fibrosis." 605 Microbiome 8: 1-13.

- 606
- 607 Dettman, J. R. and R. Kassen (2021). "Evolutionary genomics of niche-specific adaptation to the cystic 608 fibrosis lung in Pseudomonas aeruginosa." Molecular biology and evolution 38(2): 663-675.
- 609

610 Dias, R., & Torkamani, A. (2019). Artificial intelligence in clinical and genomic diagnostics. Genome 611 medicine, 11(1), 1-12.

- 612
- 613 Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002). Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric
- 614
- 615 pulmonology, 34(2), 91-100.
- 616

- 617 Evre, D. W., D. De Silva, K. Cole, J. Peters, M. J. Cole, Y. H. Grad, W. Demczuk, I. Martin, M. R. Mulvev 618 and D. W. Crook (2017). "WGS to predict antibiotic MICs for Neisseria gonorrhoeae." Journal of
- 619 Antimicrobial Chemotherapy 72(7): 1937-1947.
- 620
- 621 Firoz, A., M. Haris, K. Hussain, M. Raza, D. Verma, M. Bouchama, K. S. Namig and S. Khan (2021). "Can 622 Targeting Iron Help in Combating Chronic Pseudomonas Infection? A Systematic Review." Cureus 13(3).
- 623
- 624 Flight, W. G., A. Smith, C. Paisey, J. R. Marchesi, M. J. Bull, P. J. Norville, K. J. Mutton, A. K. Webb, R.
- 625 J. Bright-Thomas and A. M. Jones (2015). "Rapid detection of emerging pathogens and loss of microbial 626 diversity associated with severe lung disease in cystic fibrosis." Journal of clinical microbiology 53(7): 627 2022-2029.
- 628
- 629 Folkesson, A., Jelsbak, L., Yang, L., Johansen, H. K., Ciofu, O., Høiby, N., & Molin, S. (2012). Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nature Reviews
- 630
- 631 Microbiology, 10(12), 841-851. 632
- 633 Fothergill, J. L., Walshaw, M. J., & Winstanley, C. (2012). Transmissible strains of Pseudomonas 634 aeruginosa in cystic fibrosis lung infections. European Respiratory Journal, 40(1), 227-238.
- 635 Goddard, A. F., B. J. Staudinger, S. E. Dowd, A. Joshi-Datar, R. D. Wolcott, M. L. Aitken, C. L. Fligner
- 636 and P. K. Singh (2012). "Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of
- 637 upper-airway specimens can misrepresent lung microbiota." Proceedings of the National Academy of
- 638 Sciences 109(34): 13769-13774.
- 639 Harris, J. K., B. D. Wagner, E. T. Zemanick, C. E. Robertson, M. J. Stevens, S. L. Heltshe, S. M. Rowe and
- 640 S. D. Sagel (2020). "Changes in airway microbiome and inflammation with ivacaftor treatment in patients
- 641 with cystic fibrosis and the G551D mutation." Annals of the American Thoracic Society 17(2): 212-220.
- 642 Hisert, K. B., S. L. Heltshe, C. Pope, P. Jorth, X. Wu, R. M. Edwards, M. Radey, F. J. Accurso, D. J. Wolter 643 and G. Cooke (2017). "Restoring cystic fibrosis transmembrane conductance regulator function reduces 644 airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections." American 645 journal of respiratory and critical care medicine 195(12): 1617-1628.
- 646
- 647 Javan, A. O., Shokouhi, S., & Sahraei, Z. (2015). A review on colistin nephrotoxicity. European journal of 648 clinical pharmacology, 71(7), 801-810.
- 649
- 650 Jolly, A. L., D. Takawira, O. O. Oke, S. A. Whiteside, S. W. Chang, E. R. Wen, K. Quach, D. J. Evans and
- 651 S. M. J. Fleiszig (2015). "Pseudomonas aeruginosa-induced bleb-niche formation in epithelial cells is 652 independent of actinomyosin contraction and enhanced by loss of cystic fibrosis transmembrane-
- 653 conductance regulator osmoregulatory function." MBio 6(2).
- 654 Ke, Guolin, et al. "Lightgbm: A highly efficient gradient boosting decision tree." Advances in neural 655 information processing systems 30 (2017): 3146-3154.
- 656 Klockgether, J., N. Cramer, S. Fischer, L. Wiehlmann and B. Tümmler (2018). "Long-term microevolution
- 657 of Pseudomonas aeruginosa differs between mildly and severely affected cystic fibrosis lungs." American
- 658 journal of respiratory cell and molecular biology 59(2): 246-256.
- 659 Koboldt, D. C., Q. Zhang, D. E. Larson, D. Shen, M. D. McLellan, L. Lin, C. A. Miller, E. R. Mardis, L.
- 660 Ding and R. K. Wilson (2012). "VarScan 2: somatic mutation and copy number alteration discovery in 661
 - cancer by exome sequencing." Genome Research 22(3): 568-576.

 Kosorok, M. R., L. Zeng, S. E. West, M. J. Rock, M. L. Splaingard, A. Laxova, C. G. Green, J. Collins P. M. J. P., Farrell (2001). "Acceleration of lung disease in children with cystic fibrosis after Pseudoma aeruginosa acquisition." Pediatric Pulmonology 32(4): 277-287. Kresse, A. U., S. D. Dinesh, K. Larbig and U. J. M. m. Römling (2003). "Impact of large chromosc inversions on the adaptation and evolution of Pseudomonas aeruginosa chronically colonizing c? fibrosis lungs." Molecular Microbiology 47(1): 145-158. Kuhn, M. and K. Johnson (2013). Over-Fitting and Model Tuning. <u>Applied Predictive Modeling</u>. 1 York, NY, Springer New York: 61-92. Kumru, B., Emiralioğlu, N., & Ozel, H. G. (2018). Does body mass index affect lung function in pati with cystic fibrosis?. <u>Clinical Nutrition</u>, 37, 891. Le, T. T., W. Fu and J. H. Moore (2019). "Scaling tree-based automated machine learning to biomed big data with a feature set selector." <u>Bioinformatics</u> 36(1): 250-256. Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (20 Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-span regressions. <u>Mbio</u>, 11(4) Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abceasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from mategenomic analysis of sputum samples from patients with cystic fibrosis. <u>Journal of clinical microbiology</u>, 57(6). Macesie, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20 Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G.,	662 663 664	Koehrsen, https://github.	W. com/Wil	(2019). IKoehrsen/fe	Feature eature-selecto	Selector: r	Feature	Selection	in	Python.
 Kresse, A. U., S. D. Dinesh, K. Larbig and U. J. M. m. Römling (2003). "Impact of large chromoss inversions on the adaptation and evolution of Pseudomonas aeruginosa chronically colonizing cy fibrosis lungs." <u>Molecular Microbiology</u> 47(1): 145-158. Kuhn, M. and K. Johnson (2013). Over-Fitting and Model Tuning. <u>Applied Predictive Modeling</u>. 1 York, NY, Springer New York: 61-92. Kumru, B., Emiralioğlu, N., & Ozel, H. G. (2018). Does body mass index affect lung function in pati with cystic fibrosis?. <u>Clinical Nutrition</u>, 37, S91. Le, T. T., W. Fu and J. H. Moore (2019). "Scaling tree-based automated machine learning to biomed big data with a feature set selector." <u>Bioinformatics</u> 36(1): 250-256. Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (20 Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-span regressions. <u>Mbio</u>, 11(4) Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical microbiology</i> (2014). 52:425-437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20 Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning ana of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <u>Journal of clinical microbiology</u>, 57(6). Mahé, P., &	665 666 667 668	Kosorok, M. R., L. Zeng, S. E. West, M. J. Rock, M. L. Splaingard, A. Laxova, C. G. Green, J. Collins and P. M. J. P. p. Farrell (2001). "Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition." <u>Pediatric Pulmonology</u> 32 (4): 277-287.								
 Kuhn, M. and K. Johnson (2013). Over-Fitting and Model Tuning. <u>Applied Predictive Modeling</u>. 1 York, NY, Springer New York: 61-92. Kumru, B., Emiralioğlu, N., & Ozel, H. G. (2018). Does body mass index affect lung function in pati with cystic fibrosis?. <u>Clinical Nutrition</u>, 37, S91. Le, T. T., W. Fu and J. H. Moore (2019). "Scaling tree-based automated machine learning to biomet big data with a feature set selector." <u>Bioinformatics</u> 36(1): 250-256. Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (20 Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-span regressions. <u>Mbio</u>, 11(4) Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schnieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical</i> <i>microbiology</i> (2014). 52:425-437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20 Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijct, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <i>Journal of clinical microbiology</i>, 57(6) Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johanse	670 671 672 673	Kresse, A. U., S. D. Dinesh, K. Larbig and U. J. M. m. Römling (2003). "Impact of large chromosomal inversions on the adaptation and evolution of Pseudomonas aeruginosa chronically colonizing cystic fibrosis lungs." <u>Molecular Microbiology</u> 47 (1): 145-158.								
 Kumru, B., Emiralioğlu, N., & Ozel, H. G. (2018). Does body mass index affect lung function in pati with cystic fibrosis?. <u>Clinical Nutrition</u>, 37, S91. Le, T. T., W. Fu and J. H. Moore (2019). "Scaling tree-based automated machine learning to biomet big data with a feature set selector." <u>Bioinformatics</u> 36(1): 250-256. Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (20 Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-span regressions. <u>Mbio</u>, 11(4) Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical microbiology</i> (2014). 52:425–437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20 Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <u>Journal of clinical microbiology</u>, 57(6). Maké, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M.,	674 675 676	Kuhn, M. and York, NY, Sp	1 K. Johr ringer Ne	nson (2013). ew York : 61-	Over-Fitting -92.	g and Model 7	Funing. <u>App</u>	lied Predictive	<u>e Model</u>	<u>ling</u> . New
 Le, T. T., W. Fu and J. H. Moore (2019). "Scaling tree-based automated machine learning to biomece big data with a feature set selector." <u>Bioinformatics</u> 36(1): 250-256. Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (20) Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-span regressions. <u>Mbio</u>, 11(4) Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical microbiology</i> (2014). 52:425-437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20) Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <i>Journal of clinical microbiology</i>, 57(6). Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature G</u>	677 678 679	Kumru, B., Emiralioğlu, N., & Ozel, H. G. (2018). Does body mass index affect lung function in patients with cystic fibrosis?. <u>Clinical Nutrition</u> , 37, S91.								
 Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (20 Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-span regressions. <u>Mbio</u>, 11(4) Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical microbiology</i> (2014). 52:425–437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20 Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <u>Journal of clinical microbiology</u>, 57(6) Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, 47(1), 57. 	680 681 682	Le, T. T., W. Fu and J. H. Moore (2019). "Scaling tree-based automated machine learning to biomedical big data with a feature set selector." <u>Bioinformatics</u> 36 (1): 250-256.								
 Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Du (2009). "The Sequence Alignment/Map format and SAMtools." <u>Bioinformatics</u> 25(16): 2078-2079. Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical microbiology</i> (2014). 52:425–437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20) Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predict antibiotic resistance in Escherichia coli bloodstream infections. <i>Journal of clinical microbiology</i>, 57(6) Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, <i>47</i>(1), 57. 	683 684 685 686	Lees, J. A., Mai, T. T., Galardini, M., Wheeler, N. E., Horsfield, S. T., Parkhill, J., & Corander, J. (2020). Improved prediction of bacterial genotype-phenotype associations using interpretable pangenome-spanning regressions. <u>Mbio</u> , 11(4)								
 Lim YW, Evangelista III JS, Schmieder R, Bailey B, Haynes M, <i>et al.</i> Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. <i>Journal of clinical</i> <i>microbiology</i> (2014). 52:425–437. Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20) Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <i>Journal of clinical microbiology</i>, 57(6) Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, <i>47</i>(1), 57. 	687 688 689	Li, H., B. Han (2009). "The S	ndsaker, A Sequence	A. Wysoker, Alignment/	T. Fennell, . Map format a	J. Ruan, N. Ho and SAMtools	omer, G. Ma ." <u>Bioinform</u>	rth, G. Abecas atics 25 (16): 2	sis and 1 2078-202	R. Durbin 79.
 Macesic, N., Don't Walk, O. J. B., Pe'er, I., Tatonetti, N. P., Peleg, A. Y., & Uhlemann, A. C. (20) Predicting phenotypic polymyxin resistance in Klebsiella pneumoniae through machine learning anal of genomic data. <u>Msystems</u>, 5(3). MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. <u>Journal of clinical microbiology</u>, 57(6) Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, 47(1), 57. 	690 691 692 693	Lim YW, Eva metagenomic <u>microbiology</u>	ngelista l analysis (2014). 5	III JS, Schm of sputum sa 2:425–437.	ieder R, Baile Imples from J	ey B, Haynes l patients with c	M, <i>et al</i> . Clin ystic fibrosis	ical insights fi . <i>Journal of cl</i>	rom <u>!inical</u>	
 MacFadden, D. R., Melano, R. G., Coburn, B., Tijet, N., Hanage, W. P., & Daneman, N. (2019). Compa patient risk factor-, sequence type-, and resistance locus identification-based approaches for predic antibiotic resistance in Escherichia coli bloodstream infections. Journal of clinical microbiology, 57(6) Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, 47(1), 57. 	694 695 696 697	Macesic, N., Predicting pho of genomic da	Don't Wa enotypic ata. <u>Msys</u>	alk, O. J. B. polymyxin r <u>tems</u> , 5(3).	, Pe'er, I., Ta esistance in I	atonetti, N. P. Klebsiella pne	, Peleg, A. Y umoniae thro	7., & Uhlema ough machine	nn, A. (learning	C. (2020). g analysis
 Mahé, P., & Tournoud, M. (2018). Predicting bacterial resistance from whole-genome sequences usin mers and stability selection. <u>BMC bioinformatics</u>, 19(1), 1-11. Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths or hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, 47(1), 57. 	698 699 700 701	MacFadden, I patient risk fa antibiotic resi	D. R., Mel actor-, se stance in	lano, R. G., C quence type Escherichia	Coburn, B., T. -, and resista coli bloodstr	ijet, N., Hanag ince locus ide eam infections	e, W. P., & E ntification-b s. <u>Journal of c</u>	Daneman, N. (2 ased approach clinical microl	2019). C ies for j biology,	omparing predicting 57(6).
 Marvig, R. L., H. K. Johansen, S. Molin and L. Jelsbak (2013). "Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths or hypermutators." <u>PloS genetics</u> 9(9): e1003741. Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, 47(1), 57. 	702 703 704	Mahé, P., & T mers and stab	Fournoud ility selec	, M. (2018). ction. <u>BMC 1</u>	Predicting ba	acterial resista <u>s</u> , 19(1), 1-11.	nce from wh	ole-genome se	equence	s using k-
 Marvig, R. L., Sommer, L. M., Molin, S., & Johansen, H. K. (2015). Convergent evolution and adapta of Pseudomonas aeruginosa within patients with cystic fibrosis. <u>Nature Genetics</u>, <i>47</i>(1), 57. 	705 706 707 708	Marvig, R. L. lineage of Pse hypermutators	, H. K. Jo eudomona s." <u>PloS g</u>	bhansen, S. M s aeruginosa genetics 9 (9)	Molin and L a reveals path : e1003741.	Jelsbak (2013) oadaptive mu	. "Genome a tations and d	nalysis of a tra istinct evolutio	ansmiss onary pa	ible aths of
	709 710 711	Marvig, R. L. of Pseudomor	, Sommer nas aerugi	r, L. M., Mo inosa within	lin, S., & Joh patients with	ansen, H. K. (cystic fibrosi	2015). Conv s. <u>Nature Ge</u> r	ergent evolution etics, 47(1), 5	on and a 57.	adaptation

Méric, G., L. Mageiros, J. Pensar, M. Laabei, K. Yahara, B. Pascoe, N. Kittiwan, P. Tadee, V. Post, S.
Lamble, R. Bowden, J. E. Bray, M. Morgenstern, K. A. Jolley, M. C. J. Maiden, E. J. Feil, X. Didelot, M.
Miragaia, H. de Lencastre, T. F. Moriarty, H. Rohde, R. Massey, D. Mack, J. Corander and S. K. Sheppard
(2018). "Disease-associated genotypes of the commensal skin bacterium Staphylococcus epidermidis."
Nature Communications 9(1): 5034.

- Mobegi, F. M., Cremers, A. J., De Jonge, M. I., Bentley, S. D., Van Hijum, S. A., & Zomer, A. (2017).
 Deciphering the distance to antibiotic resistance for the pneumococcus using genome sequencing data.
 Scientific reports, 7(1), 1-13.
- Mowat, E., S. Paterson, J. L. Fothergill, E. A. Wright, M. J. Ledson, M. J. Walshaw, M. A. Brockhurst and
 C. Winstanley (2011). "Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis
 chronic infections." <u>American journal of respiratory and critical care medicine</u> 183(12): 1674-1679.
- Pedregosa, F., G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer,
 R. Weiss and V. Dubourg (2011). "Scikit-learn: Machine learning in Python." <u>The Journal of machine</u>
 <u>Learning research</u> 12: 2825-2830.
- Pincus, N. B., E. A. Ozer, J. P. Allen, M. Nguyen, J. J. Davis, D. R. Winter, C.-H. Chuang, C.-H. Chiu, L.
 Zamorano and A. Oliver (2020). "A genome-based model to predict the virulence of Pseudomonas aeruginosa isolates." <u>Mbio</u> 11(4).
- Poudyal, B., & Sauer, K. (2018). The ABC of biofilm drug tolerance: the MerR-like regulator BrlR is an
 activator of ABC transport systems, with PA1874-77 contributing to the tolerance of Pseudomonas
 aeruginosa biofilms to tobramycin. <u>Antimicrobial agents and chemotherapy</u>, 62(2).
- Raschka, S. (2018). MLxtend: Providing machine learning and data science utilities and extensions to
 Python's scientific computing stack. Journal of open source software, 3(24), 638.
- Recker, M., M. Laabei, M. S. Toleman, S. Reuter, R. B. Saunderson, B. Blane, M. E. Török, K. Ouadi, E.
 Stevens and M. Yokoyama (2017). "Clonal differences in Staphylococcus aureus bacteraemia-associated
 mortality." <u>Nature microbiology</u> 2(10): 1381-1388.
- Saber, M. M., & Shapiro, B. J. (2020). Benchmarking bacterial genome-wide association study methods
 using simulated genomes and phenotypes. <u>Microbial genomics</u>, 6(3).
- Shanthikumar, S., M. N. Neeland, R. Saffery and S. Ranganathan (2019). "Gene modifiers of cystic
 fibrosis lung disease: a systematic review." <u>Pediatric pulmonology</u> 54(9): 1356-1366.
- Smith, E. E., D. G. Buckley, Z. Wu, C. Saenphimmachak, L. R. Hoffman, D. A. D'Argenio, S. I. Miller, B.
 W. Ramsey, D. P. Speert and S. M. Moskowitz (2006). "Genetic adaptation by Pseudomonas aeruginosa to
 the airways of cystic fibrosis patients." <u>Proceedings of the National Academy of Sciences</u> 103(22): 84878492.
- 755

717

721

733

737

- Snell, G. I., Bennetts, K., Bartolo, J., Levvey, B., Griffiths, A., Williams, T., & Rabinov, M. (1998). Body
 mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. The
 Journal of heart and lung transplantation: the official publication of the International Society for Heart
 Transplantation, 17(11), 1097-1103.
- 760

- Somayaji, R., J. C. Lam, M. G. Surette, B. Waddell, H. R. Rabin, C. D. Sibley, S. Purighalla and M. D.
 Parkins (2017). "Long-term clinical outcomes of 'Prairie Epidemic Strain'Pseudomonas aeruginosa
- 763 infection in adults with cystic fibrosis." Thorax 72(4): 333-339.
- 764

765 Stressmann, F. A., G. B. Rogers, C. J. Van Der Gast, P. Marsh, L. S. Vermeer, M. P. Carroll, L. Hoffman,

- 766 T. W. V. Daniels, N. Patel and B. Forbes (2012). "Long-term cultivation-independent microbial diversity
- analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability andresilience." Thorax 67(10): 867-873.
- 769
- Svetnik, V., Liaw, A., Tong, C., Culberson, J. C., Sheridan, R. P., & Feuston, B. P. (2003). Random forest:
 a classification and regression tool for compound classification and QSAR modeling. Journal of chemical
- information and computer sciences, 43(6), 1947-1958.
- Turcios, N. L. (2020). Cystic fibrosis lung disease: An overview. <u>Respiratory care</u>, 65(2), 233-251.
- Tümmler, B. (2006). Clonal variations in Pseudomonas aeruginosa. In Pseudomonas (pp. 35-68). Springer,
 Boston, MA.
- 776

780

- Van Der Gast, C. J., A. W. Walker, F. A. Stressmann, G. B. Rogers, P. Scott, T. W. Daniels, M. P. Carroll,
 J. Parkhill and K. D. Bruce (2011). "Partitioning core and satellite taxa from within cystic fibrosis lung
 bacterial communities." <u>The ISME journal</u> 5(5): 780-791.
- Virtanen, P., R. Gommers, T. E. Oliphant, M. Haberland, T. Reddy, D. Cournapeau, E. Burovski, P.
 Peterson, W. Weckesser and J. Bright (2020). "SciPy 1.0: fundamental algorithms for scientific computing
 in Python." <u>Nature methods</u> 17(3): 261-272.
- Waskom, M. L. (2021). Seaborn: statistical data visualization. Journal of Open Source Software, 6(60),
 3021.
- Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS,
 Valle D, eds. Metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill,
 2001:5121-5188.
- 791

- Williams, D., B. Evans, S. Haldenby, M. J. Walshaw, M. A. Brockhurst, C. Winstanley and S. Paterson
 (2015). "Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections."
 American journal of respiratory and critical care medicine 191(7): 775-785.
- 796 Zhang, L., & Mah, T. F. (2008). Involvement of a novel efflux system in biofilm-specific resistance to 797 antibiotics. Journal of bacteriology, 190(13), 4447-4452.
- Zhao, C. Y., Y. Hao, Y. Wang, J. J. Varga, A. A. Stecenko, J. B. Goldberg and S. P. Brown (2020).
 "Microbiome data enhances predictive models of lung function in people with cystic fibrosis." <u>The Journal</u> of Infectious Diseases. 2020; jiaa655
- 801 Zhao, J., P. D. Schloss, L. M. Kalikin, L. A. Carmody, B. K. Foster, J. F. Petrosino, J. D. Cavalcoli, D. R.
- 802 VanDevanter, S. Murray and J. Z. Li (2012). "Decade-long bacterial community dynamics in cystic fibrosis
- 803 airways." <u>Proceedings of the National Academy of Sciences</u> 109(15): 5809-5814.
- 804